Lundbeck starts clinical phase IIa with Lu AA24493 (cEPO) in Friedreich's ataxia in a study also assessing efficacy via biomarkers

PR-inside.com,
London, November , 02, 2009
 
Keywords: H. Lundbeck A/S, phase IIa clinical studies, project Lu AA24493, safety  and
tolerability,  Friedreich's ataxia,  carbamoylated form of human erythropoietin (EPO), loss of haematopoietic effects,  neuronal damage,

----------------------------------------------------------

Pharmacy Europe,
Latest News, Monday 2nd November 2009

Lundbeck starts clinical phase IIa with Lu AA24493 (cEPO)

---------------------------------------------------------

Reuters.com
Mon Nov 2, 2009 5:10am EST

Lundbeck says expands stroke drug candidate trials